All Metrics
PODD Valuation Metrics
PODD Stock Price Metrics
PODD Dividend Metrics
PODD Growth Rate Metrics
PODD Discounted Cash Flow Metrics
| Fair Value Price | - |
| Margin of Safety | - |
PODD Revenue Metrics
PODD PE Ratio Metrics
| PE Ratio | 34.62 |
| PE Ratio Avg TTM | 72.50 |
| PE Ratio Avg 3Y | 69.23 |
| Current VS TTM Avg | -52.25% |
| Current VS 3Y Avg | -49.99% |
| Current VS 5Y Avg | -86.38% |
PODD PS Ratio Metrics
| PS Ratio | 3.60 |
| PS Ratio Avg TTM | 7.61 |
| PS Ratio Avg 3Y | 8.56 |
| Current VS TTM Avg | -52.68% |
| Current VS 3Y Avg | -57.95% |
| Current VS 5Y Avg | -69.46% |
PODD PB Ratio Metrics
| PB Ratio | 8.02 |
| PB Ratio Avg TTM | 13.30 |
| PB Ratio Avg 3Y | 16.65 |
| Current VS TTM Avg | -39.69% |
| Current VS 3Y Avg | -51.84% |
| Current VS 5Y Avg | -69.77% |
PODD Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 25.36 |
| PFCF Ratio Avg TTM | 50.01 |
| PFCF Ratio Avg 3Y | 64.81 |
| Current VS TTM Avg | -49.29% |
| Current VS 3Y Avg | -60.87% |
| Current VS 5Y Avg | -60.87% |
PODD Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.73 |
| Debt/Equity Ratio Avg TTM | 0.88 |
| Debt/Equity Ratio Avg 3Y | 1.51 |
| Current VS TTM Avg | -17.47% |
| Current VS 3Y Avg | -51.78% |
| Current VS 5Y Avg | -63.51% |
PODD PEG Ratio Metrics
| PEG Ratio | 0.35 |
| PEG Ratio Avg TTM | 0.23 |
| PEG Ratio Avg 3Y | 2.94 |
| Current VS TTM Avg | +55.56% |
| Current VS 3Y Avg | -88.08% |
| Current VS 5Y Avg | -88.86% |
PODD FCF Yield
| FCF Yield | 3.94% |
| FCF Yield Avg TTM | 1.96% |
| FCF Yield Avg 3Y | 1.46% |
| Current VS TTM Avg | +101.10% |
| Current VS 3Y Avg | +170.46% |
| Current VS 5Y Avg | +170.46% |
PODD Earnings Yield
| Earnings Yield | 2.89% |
| Earnings Yield Avg TTM | 1.55% |
| Earnings Yield Avg 3Y | 1.57% |
| Current VS TTM Avg | +86.06% |
| Current VS 3Y Avg | +84.64% |
| Current VS 5Y Avg | +164.13% |
PODD EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 21.53 |
| Ev/Ebit Ratio Avg TTM | 45.57 |
| Ev/Ebit Ratio Avg 3Y | 59.31 |
| Current VS TTM Avg | -52.75% |
| Current VS 3Y Avg | -63.70% |
| Current VS 5Y Avg | -84.46% |
PODD EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 18.99 |
| Ev/Ebitda Ratio Avg TTM | 42.95 |
| Ev/Ebitda Ratio Avg 3Y | 48.11 |
| Current VS TTM Avg | -55.79% |
| Current VS 3Y Avg | -60.53% |
| Current VS 5Y Avg | -81.32% |
PODD EV/Assets Ratio Metrics
| Ev/Assets Ratio | 3.66 |
| Ev/Assets Ratio Avg TTM | 5.91 |
| Ev/Assets Ratio Avg 3Y | 5.95 |
| Current VS TTM Avg | -38.04% |
| Current VS 3Y Avg | -38.54% |
| Current VS 5Y Avg | -50.35% |
PODD EV/Sales Ratio Metrics
| Ev/Sales Ratio | 3.76 |
| Ev/Sales Ratio Avg TTM | 7.76 |
| Ev/Sales Ratio Avg 3Y | 8.94 |
| Current VS TTM Avg | -51.52% |
| Current VS 3Y Avg | -57.93% |
| Current VS 5Y Avg | -69.15% |
PODD Current Ratio Metrics
| Current Ratio | 2.49 |
| Current Ratio Avg TTM | 2.96 |
| Current Ratio Avg 3Y | 3.28 |
| Current VS TTM Avg | -16.01% |
| Current VS 3Y Avg | -24.25% |
| Current VS 5Y Avg | -38.07% |
PODD Quick Ratio Metrics
| Quick Ratio | 1.81 |
| Quick Ratio Avg TTM | 2.30 |
| Quick Ratio Avg 3Y | 2.37 |
| Current VS TTM Avg | -21.04% |
| Current VS 3Y Avg | -23.41% |
| Current VS 5Y Avg | -41.22% |
PODD ROIC Metrics
| ROIC | 13.62% |
| ROIC Avg 3Y | 8.97% |
| ROIC Avg 5Y | 7.27% |
| Current VS 3Y Avg | +51.84% |
| Current VS 5Y Avg | +87.43% |
| Current VS 10Y Avg | +537.80% |
PODD Return on Assets Metrics
| ROA | 7.75% |
| ROA Avg TTM | 10.65% |
| ROA Avg 3Y | 7.37% |
| Current VS TTM Avg | -27.23% |
| Current VS 3Y Avg | +5.19% |
| Current VS 5Y Avg | +51.71% |
PODD Return on Equity Metrics
| ROE | 16.31% |
| ROE Avg TTM | 25.41% |
| ROE Avg 3Y | 19.99% |
| Current VS TTM Avg | -35.83% |
| Current VS 3Y Avg | -18.41% |
| Current VS 5Y Avg | +16.35% |
PODD Net Profit Margin Metrics
| Net Profit Margin | 11.96% |
| Net Profit Margin Avg TTM | 9.40% |
| Net Profit Margin Avg 3Y | 11.30% |
| Current VS TTM Avg | +27.20% |
| Current VS 3Y Avg | +5.87% |
| Current VS 5Y Avg | +32.61% |
Last Updated: Thursday, June 25, 2026
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy